Income Tax Disclosure [Abstract]
Valuation allowance, increase amount
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Federal net operating loss carryforwards
Operating Loss Carryforwards
Deferred tax assets, alternative minimum tax
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax
Operating loss carryforwards from excess tax deduction on stock option activity
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
Unrecognized tax benefits
Unrecognized Tax Benefits
Accounting Policies [Abstract]
Use of Estimates
Use of Estimates, Policy [Policy Text Block]
Basis of Presentation
Basis of Accounting, Policy [Policy Text Block]
Cash Equivalents
Cash, Cash Equivalents, and Short-term Investments [Text Block]
Restricted Cash and Cash Equivalents
Restricted Cash and Cash Equivalents [Policy Text Block]
Restricted Cash and Cash Equivalents [Policy Text Block]
Concentration of Credit Risk
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Accounts Receivable
Trade and Other Accounts Receivable, Policy [Policy Text Block]
Inventory
Inventory, Policy [Policy Text Block]
Property, Plant and Equipment
Property, Plant and Equipment, Policy [Policy Text Block]
Warrant Liability
Derivatives, Policy [Policy Text Block]
Revenue Recognition
Revenue Recognition, Policy [Policy Text Block]
Research and Development
Research and Development Expense, Policy [Policy Text Block]
Goodwill
Goodwill, Policy [Policy Text Block]
Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill.
Share-based Compensation
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]
Income Taxes
Income Tax, Policy [Policy Text Block]
Net Loss per Share
Earnings Per Share, Policy [Policy Text Block]
Fair Value of Financial Instruments
Fair Value of Financial Instruments, Policy [Policy Text Block]
Legal Contingencies
Commitments and Contingencies, Policy [Policy Text Block]
Segment Reporting
Segment Reporting, Policy [Policy Text Block]
Recent Accounting Pronouncements
New Accounting Pronouncements, Policy [Policy Text Block]
Payables and Accruals [Abstract]
Bonus
Accrued Bonuses, Current
Professional fees
Accrued Professional Fees, Current
Vacation
Accrued Vacation, Current
Other (primarily R&D vendors and CMOs)
Other Accrued Liabilities, Current
Accrued expenses and other current liabilities
Accrued Liabilities, Current
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Award Type [Axis]
Award Type [Axis]
Award Type [Domain]
Equity Award [Domain]
Stock Options
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of shares outstanding at beginning of period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Number of shares granted
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Number of shares exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Number of shares canceled and expired
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Number of shares outstanding at end of period
Number of shares vested and expected to vest
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Number of shares exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price outstanding at beginning of period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Weighted average exercise price, granted
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Weighted average exercise price, exercised
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Weighted average exercise price, canceled and expired
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Weighted average exercise price outstanding at end of period
Weighted average exercise price, vested and expected to vest
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Weighted average exercise price, exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted average remaining life, outstanding
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Weighted average remaining life, vested and expected to vest
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term
Weighted average remaining life, exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]
Intrinsic value, outstanding
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Intrinsic value, vested and expected to vest
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Intrinsic value, exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Equity [Abstract]
Stockholders' Equity
Stockholders' Equity Note Disclosure [Text Block]
Statement of Financial Position [Abstract]
ASSETS
Assets [Abstract]
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value
Restricted cash and cash equivalents-short term
Restricted Cash and Cash Equivalents, Current
Accounts receivable
Accounts Receivable, Net, Current
Inventory
Inventory, Net
Prepaid expenses and other current assets
Prepaid Expense and Other Assets, Current
Total current assets
Assets, Current
Property, plant and equipment, net
Property, Plant and Equipment, Net
Restricted cash and cash equivalents-long term
Restricted Cash and Cash Equivalents, Noncurrent
Deferred costs
Deferred Costs, Noncurrent
Goodwill
Goodwill
Other assets
Other Assets, Noncurrent
Total assets
Assets
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Liabilities and Equity [Abstract]
Accounts payable
Accounts Payable, Current
Accrued expenses and other current liabilities
Warrant liability
Warrants and Rights Outstanding
Total current liabilities
Liabilities, Current
Deferred revenue
Deferred Revenue, Noncurrent
Deferred income tax liability, net
Deferred Tax Liabilities, Net, Noncurrent
Other liabilities
Other Liabilities
Liabilities subject to compromise
Liabilities Subject to Compromise
Loan payable
Loans Payable
Total liabilities
Liabilities
Stockholders’ deficit
Stockholders' Equity Attributable to Parent [Abstract]
Common stock ($.0001 par value, 600,000,000 shares authorized, 78,692,612 and 54,114,296 issued and outstanding at December 31, 2016, and December 31, 2015, respectively)
Common Stock, Value, Issued
Additional paid-in capital
Additional Paid in Capital, Common Stock
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Total stockholders’ deficit
Stockholders' Equity Attributable to Parent
Total liabilities and stockholders’ deficit
Liabilities and Equity
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
Income Statement [Abstract]
Revenues
Revenues [Abstract]
Research and development
Research and Development Revenue
Revenue earned during the period arising from services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts and any other contract related to a particular project or product.
Operating expenses
Operating Expenses [Abstract]
Selling, general and administrative
Selling, General and Administrative Expense
Research and development
Research and Development Expense
Patent preparation fees
Patent Preparation Fees
The aggregate costs incurred for fees associated with the protection and expansion of patents and related intellectual property.
Litigation accrual expense
Loss Contingency, Loss in Period
Interest on PharmAthene liability
Litigation Settlement Interest
Total operating expenses
Operating Expenses
Operating loss
Operating Income (Loss)
Decrease (increase) in fair value warrant liability
Increase In Fair Value Of Warrants
Noncash expense, not otherwise specified in the taxonomy, charged against earnings in the period to adjust the fair market value of liability classified warrants to purchase common stock.
Interest expense
Interest Expense
Backstop fee - see Note 8
Backstop Fee
Backstop Fee
Other income, net
Nonoperating Income (Expense)
Reorganization items, net
Reorganization Items
Loss before income taxes
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest
Provision for income taxes
Income Tax Expense (Benefit)
Net and comprehensive loss
Net Income (Loss) Attributable to Parent
Earnings (loss) per share: basic and diluted (usd per share)
Earnings Per Share, Basic and Diluted
Weighted average shares outstanding: basic and diluted (in shares)
Weighted Average Number of Shares Outstanding, Basic and Diluted
Schedule of Property, Plant and Equipment [Table]
Property, Plant and Equipment [Table]
Property, Plant and Equipment, Type [Axis]
Property, Plant and Equipment, Type [Axis]
Property, Plant and Equipment, Type [Domain]
Property, Plant and Equipment, Type [Domain]
Lab equipment
Lab equipment [Member]
Long lived, depreciable assets that are used in the laboratory.
Computer Equipment
Computer Equipment [Member]
Furniture and Fixtures
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment [Line Items]
Receivables percentage
Receivables Percentage
Percentage of accounts receivables represented from National Institutes of Health and BARDA.
Property, plant and equipment, useful life
Property, Plant and Equipment, Useful Life
Property, Plant and Equipment [Abstract]
Property, plant and equipment
Property, Plant and Equipment [Table Text Block]
Income Taxes
Income Tax Disclosure [Text Block]
Balance Sheet Parenthetical [Abstract]
Balance Sheet Parenthetical [Abstract]
Common stock, par value
Common Stock, Par or Stated Value Per Share
Common stock, shares authorized
Common Stock, Shares Authorized
Common stock, shares issued
Common Stock, Shares, Issued
Common stock, shares outstanding
Common Stock, Shares, Outstanding
Significant Accounting Policies
Significant Accounting Policies [Text Block]
Accrued Expenses
Accrued expenses and other current liabilities [Table Text Block]
Tabular disclosure of the components of accrued liabilities and other current liabilities.
2017
Operating Leases, Future Minimum Payments Due, Next Twelve Months
2018
Operating Leases, Future Minimum Payments, Due in Two Years
2019
Operating Leases, Future Minimum Payments, Due in Three Years
2020
Operating Leases, Future Minimum Payments, Due in Four Years
Total
Operating Leases, Future Minimum Payments Due
Quarterly Financial Information [Abstract]
Unaudited Quarterly Results [Abstract]
Selling, general and administrative expense
Research and development expense
Operating loss
Net income (loss)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Reorganization [Abstract]
Reorganization [Abstract]
Legal fees
Debtor Reorganization Items, Legal and Advisory Professional Fees
Professional fees
Reorganization, Professional Fees
Amount of reorganization items related to professional fees related to entities in bankruptcy.
Trustee fees
Reorganization, Trustee fees
Amount of reorganization items for trustee fees related to entities in bankruptcy.
Other
Debtor Reorganization Items, Other Expense (Income)
Total
Restricted Stock Units (RSUs)
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Number of shares outstanding at beginning of period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Number of shares granted
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Number of shares vested
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Number of shares canceled and expired
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Number of shares outstanding at end of period
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted average grant-date fair value outstanding at beginning of period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Weighted average grant-date fair value, granted
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted average grant-date fair value, vested
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Weighted averaged grant-date fair value, canceled and expired
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Weighted average grant-date fair value outstanding at end of period
Organization and Basis of Presentation [Abstract]
Organization and Basis of Presentation [Abstract]
Schedule of Long-term Debt Instruments [Table]
Schedule of Long-term Debt Instruments [Table]
Scenario [Axis]
Scenario [Axis]
Scenario, Unspecified [Domain]
Scenario, Unspecified [Domain]
Scenario, Forecast
Scenario, Forecast [Member]
Debt Instrument Capacity by Specific Purpose [Axis]
Debt Instrument Capacity by Specific Purpose [Axis]
Debt Instrument Capacity by Specific Purpose [Axis]
Debt Instrument Capacity by Specific Purpose [Domain]
Debt Instrument Capacity by Specific Purpose [Domain]
[Domain] for Debt Instrument Capacity by Specific Purpose [Axis]
Repayment of Interests
Repayment of Interests [Member]
Repayment of Interests [Member]
Payments Related to Litigation
Payments Related to Litigation [Member]
Payments Related to Litigation [Member]
Variable Rate [Axis]
Variable Rate [Axis]
Variable Rate [Domain]
Variable Rate [Domain]
London Interbank Offered Rate (LIBOR)
London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Axis]
Debt Instrument [Axis]
Debt Instrument, Name [Domain]
Debt Instrument, Name [Domain]
Loan Agreement
Loan Agreement [Member]
Loan Agreement [Member]
Credit Facility [Axis]
Credit Facility [Axis]
Credit Facility [Domain]
Credit Facility [Domain]
Secured Debt
Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Line of credit facility
Line of Credit Facility, Maximum Borrowing Capacity
Margin for term loan
Debt Instrument, Basis Spread on Variable Rate
Capacity available for specific purpose other than for trade purchases
Line of Credit Facility, Capacity Available for Specific Purpose Other than for Trade Purchases
Additional borrowing capacity
Line of Credit Facility, Additional Borrowing Capacity
Line of Credit Facility, Additional Borrowing Capacity
Class of Warrant or Right [Table]
Class of Warrant or Right [Table]
Class of Warrant or Right [Axis]
Class of Warrant or Right [Axis]
Class of Warrant or Right [Domain]
Class of Warrant or Right [Domain]
Subscription Right
Subscription Right [Member]
Subscription Right [Member]
Equity Components [Axis]
Equity Components [Axis]
Equity Component [Domain]
Equity Component [Domain]
Warrants
Warrant [Member]
Antidilutive Securities [Axis]
Antidilutive Securities [Axis]
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name [Domain]
Class of Warrant or Right [Line Items]
Class of Warrant or Right [Line Items]
Warrants purchased, value
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Exercise price of warrants
Class of Warrant or Right, Exercise Price of Warrants or Rights
Exercisable period for warrants (in years)
Class of Warrant or Right, Period from which Warrants or Rights are Exercisable
Class of Warrant or Right, Period from which Warrants or Rights are Exercisable
Warrants that can be purchased, shares
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right
Fair value of warrant
Sale of Stock [Axis]
Sale of Stock [Axis]
Sale of Stock [Domain]
Sale of Stock [Domain]
Private Placement
Private Placement [Member]
Class of Stock [Axis]
Class of Stock [Axis]
Class of Stock [Domain]
Class of Stock [Domain]
Common Stock
Common Stock [Member]
Equity Rights
Equity Rights [Member]
Equity Rights [Member]
Capital units, authorized
Capital Units, Authorized
Preferred stock, shares authorized
Preferred Stock, Shares Authorized
Equity offering
Proceeds from Issuance of Warrants
Issuance of common stock associated with rights offering, shares
Stock Issued During Period, Shares, Rights Offering
Stock Issued During Period, Shares, Rights Offering
Amount to be invested by each right to purchase securities (in dollars per share)
Class of Warrant or Right, Amount to be Invested by Each Warrant or Right to Purchase Securities, Per Share
Class of Warrant or Right, Amount to be Invested by Each Warrant or Right to Purchase Securities, Per Share
Stock Issued During Period, Shares, New Issues
Stock Issued During Period, Shares, New Issues
Volume of weighted average price during market hours (as a percent)
Class of Warrant or Right, Exercise Price of Warrants or Rights, Volume of Weighted Average Price During Market Hours, Percentage
Class of Warrant or Right, Exercise Price of Warrants or Rights, Volume of Weighted Average Price During Market Hours, Percentage
Share price
Share Price
Backstop fee
Payments of Stock Issuance Costs
Risk free interest rate (as a percent)
Fair Value Assumptions, Risk Free Interest Rate
Expected dividend rate (as a percent)
Fair Value Assumptions, Expected Dividend Rate
Expected term (in years)
Fair Value Assumptions, Expected Term
Expected volatility rate (as a percent)
Fair Value Assumptions, Expected Volatility Rate
Increase in fair value of warrant liability
Liabilities Subject to Compromise [Abstract]
Liabilies subject to compromise
Liabilies subject to compromise [Table Text Block]
[Table Text Block] for Schedule of liabilities that are subject to compromise.
Reorganization items
Reorganization items [Table Text Block]
The schedule represents a summary of reorganization items.
Deferred income tax assets:
Components of Deferred Tax Assets [Abstract]
Net operating losses
Deferred Tax Assets, Operating Loss Carryforwards
Deferred research and development costs
Deferred Tax Assets, Tax Deferred Expense
Amortization of intangible assets
Deferred Tax Assets, Goodwill and Intangible Assets
Share-based compensation
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Fixed assets
Deferred Tax Assets, Property, Plant and Equipment
Deferred revenue
Deferred Tax Assets, Deferred Income
Alternative minimum tax credits
Loss contingency
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies
Other
Deferred Tax Assets, Other
Deferred income tax assets
Deferred Tax Assets, Gross
Deferred income tax assets, net of valuation allowance
Deferred Tax Assets, Valuation Allowance
Deferred income tax assets, net of valuation allowance
Deferred Tax Assets, Net of Valuation Allowance
Deferred income tax liabilities:
Components of Deferred Tax Liabilities [Abstract]
Amortization of goodwill
Deferred Tax Liabilities, Goodwill
Capitalized contract costs
Deferred Tax Liabilities, Capitalized Contract Costs
Amount of deferred tax liability attributable to taxable temporary differences from capitalized contract costs.
Other
Deferred Tax Liabilities, Other
Deferred income tax liability, net
Deferred Tax Liabilities, Net
Leasehold improvements, gross
Leasehold Improvements, Gross
Computer equipment, gross
Computer Equipment
The gross amount of capitalized computer equipment costs as of the balance sheet date.
Furniture and fixtures, gross
Furniture and Fixtures, Gross
Property, plant and equipment, gross
Property, Plant and Equipment, Gross
Accumulated depreciation, depletion and amortization, property, plant, and equipment
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Property, plant and equipment, net
Inventory Disclosure [Abstract]
Work in process
Inventory, Work in Process and Raw Materials
Finished goods
Inventory, Finished Goods, Net of Reserves
Document and Entity Information [Abstract]
Document and Entity Information [Abstract]
Entity Registrant Name
Entity Registrant Name
Entity Central Index Key
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Entity Filer Category
Entity Filer Category
Trading Symbol
Trading Symbol
Document Type
Document Type
Document Period End Date
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Amendment Flag
Amendment Flag
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Entity Well-known Seasoned Issuer
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Voluntary Filers
Entity Current Reporting Status
Entity Current Reporting Status
Entity Public Float
Entity Public Float
Financial Information By Quarter
Quarterly Financial Information [Text Block]
Long-term Debt, Type [Axis]
Long-term Debt, Type [Axis]
Long-term Debt, Type [Domain]
Long-term Debt, Type [Domain]
Senior Secured Term Loan
Senior Secured Term Loan [Member]
Senior Secured Term Loan [Member]
Measurement Frequency [Axis]
Measurement Frequency [Axis]
Fair Value, Measurement Frequency [Domain]
Fair Value, Measurement Frequency [Domain]
Fair Value, Measurements, Recurring
Fair Value, Measurements, Recurring [Member]
Fair Value, Hierarchy [Axis]
Fair Value, Hierarchy [Axis]
Fair Value Hierarchy [Domain]
Fair Value Hierarchy [Domain]
Fair Value, Inputs, Level 2
Fair Value, Inputs, Level 2 [Member]
Loan outstanding
Long-term Debt
Property, Plant and Equipment
Property, Plant and Equipment Disclosure [Text Block]
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]
Current federal tax expense (benefit)
Current Federal Tax Expense (Benefit)
Current state and local tax expense (benefit)
Current State and Local Tax Expense (Benefit)
Current income tax expense (benefit)
Current Income Tax Expense (Benefit)
Deferred federal income tax expense (benefit)
Deferred Federal Income Tax Expense (Benefit)
Deferred state and local income tax expense (Benefit)
Deferred State and Local Income Tax Expense (Benefit)
Deferred income tax expense (benefit)
Deferred Income Tax Expense (Benefit)
Benefit from (provision for) income taxes
Inventory write-downs
Inventory Write-downs
Inventory write-downs included in research and development expense on the balance sheet.
Stock Appreciation Rights (SARs)
Stock Appreciation Rights (SARs) [Member]
Number of shares exercised
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period
The number of exercises made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
Number of shares exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other then Options, Exercisable Number
The number of shares into which fully or partially vested, other than stock (or unit) option plans outstanding as of the balance sheet date can be currently converted under the option plan.
Weighted average exercise price outstanding at beginning of period
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price
The weighted-average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
Weighted average exercise price granted
Share-based Compensation Arrangement by Share-based Payment Award, Options Granted, Weighted Average Excercise Price
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of granted options under the stock option plan.
Weighted average exercise price exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options Excercised, Weighted Average Excercise Price
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of exercised options under the stock option plan.
Weighted average exercise price canceled and expired
Share-based Compensation Arrangement by Share-based Payment Award, Options Canceled / Expired, Weighted Average Excercise Price
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of canceled and expired options under the stock option plan.
Weighted average exercise price outstanding at end of period
Weighted average exercise price, vested and expected to vest
Share-based Compensation Arragement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Weighted Average Excercise Price
As of the balance sheet date, the weighted average excercise price for outstanding equity instruments other than options that are fully vested of expected to vest.
Weighted average exercise price, exercisable
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Weighted average remaining life, vested and expected to vest
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Weighted Average Remaining Life
The weighted-average remaining life in years, for equity instruments other than options vested and expected to vest.
Weighted average remaining life, exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Weighted Average Remaining Life
The weighted-average remaining life in years, for excercisable equity instruments other than options.
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]
Intrinsic value outstanding
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Intrinsic Value
Amount of difference between fair value of the underlying equity instruments reserved for issuance and exercise price of equity instruments outstanding.
Intrinsic value, vested and expected to vest
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share
Intrinsic value, exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Intrinsic Value
Amount of difference between fair value of the underlying equity instrument for the issuance and exercise price of vested portions of equity instruments outstanding and currently exercisable.
Schedule of Future Minimum Rental Payments for Operating Leases
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
Schedule of quarterly financial information
Schedule of Quarterly Financial Information [Table Text Block]
Amount paid to settle claims
Bankruptcy Claims, Amount Paid to Settle Claims
Amount to be paid on effective date of plan of reorganization
Amount To Be Paid On Effective Date of Plan Of Reorganization
The amount the Company is to pay PharmAthene on the effective date of the plan of reorganization.
Payment to extend 120 days to satisfy pharmAthene claim
payment to extend 120 days to satisfy pharmAthene claim
payment to extend 120 days to satisfy pharmAthene claim
Payment to extend days to satisfy claim
Payment To Extend Days To Satisfy Claim
Total amount of payment to PharmAthene to extend the number of days to satisfy the claim.
Payments for legal settlements
Payments for Legal Settlements
Inventory
Inventory Disclosure [Text Block]
Depreciation and other amortization
Depreciation, Depletion and Amortization
Related Party Transactions [Abstract]
Schedule of Related Party Transactions, by Related Party [Table]
Schedule of Related Party Transactions, by Related Party [Table]
Related Party [Axis]
Related Party [Axis]
Related Party [Domain]
Related Party [Domain]
Affiliated Entity
Affiliated Entity [Member]
Member of Board of Directors
Management [Member]
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
Free rent period
Free Rent Period
Free Rent Period in months allowed under the sublease.
Monthly rental payments first five years
Monthly Rental Payments First Five Years
The amount of the monthly rental payments due under the sublease entered into for the first five years.
Initial rent period
Initial Rent Period
Represents the number of years for the initial rent period of five years and related monthly payments.
Monthly rental payments after five years
Monthly Rental Payments After Five Years
The amount of the monthly rental payments due under the sublease entered into after the first five years.
Rent period after first five years
Rent Period After First Five Years
Represents the amount of years after the initial rent period of first five years of which monthly rental payments will increase.
Legal fees
Legal Fees
Accounts payable to related party
Accounts Payable, Related Parties
Range [Axis]
Range [Axis]
Range [Domain]
Range [Domain]
Maximum
Maximum [Member]
Minimum
Minimum [Member]
Number of shares authorized
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized
Stock-based compensation expense
Allocated Share-based Compensation Expense
Unrecognized stock-based compensation cost, net of estimated forfeitures
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized
Weighted average remaining requisite service period (in years)
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition
Fair value of vested stock options
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Total intrinsic value of stock options exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Performance-based stock options
Share-based Compensation Arrangement by Share-based Payment Award, Options, Performance Based, Number
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date subject to performance conditions under the option plan.
Award vesting period
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period
Expiration period
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period
Maximum number of shares to be issued
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares that Could Be Issued
Share-based compensation arrangement by share-based payment award, maximum number of shares that could be issued
Fair value of vested stock appreciation rights
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value
Unrecognized stock-based compensation cost
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options
Fair value of stock compensation vested
Stock Issued During Period, Value, Restricted Stock Award, Gross
Warrant liability at September 02, 2016 - issuance date
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value
Increase in fair value of warrant liability
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Warrant liability at December 31, 2016
Number of subscription rights called by each equity right
Related Party Transactions
Related Party Transactions Disclosure [Text Block]
Procurement Contract [Table]
Procurement Contract [Table]
Procurement Contract [Table]
Subsequent Event Type [Axis]
Subsequent Event Type [Axis]
Subsequent Event Type [Domain]
Subsequent Event Type [Domain]
Subsequent Event
Subsequent Event [Member]
Procurement Contract [Axis]
Procurement Contract [Axis]
Procurement Contract [Axis]
Procurement Contract [Domain]
Procurement Contract [Domain]
Procurement Contract [Domain]
BARDA Contract
Barda Contract [Member]
Barda Contract [Member]
Procurement Contract [Line Items]
Procurement Contract [Line Items]
Procurement Contract [Line Items]
Proceeds from manufacture and physical delivery of course, government contractses
Proceeds From Manufacture And Physical Delivery Of Courses, Government Contracts
Proceeds from manufacture and physical delivery of courses, government contracts.
Government contract, total number of courses required to be delivered
Government Contract, Total Number of Courses Required to Be Delivered
Government Contract, Total Number of Courses Required to Be Delivered
Reduced holdback amount
Reduced holdback amount
Reduced holdback be received from BARDA
Research and Development [Abstract]
Procurement Contract and Research Agreements
Procurement Contract and Research Agreements [Text Block]
The entire disclosure for procurement contracts and research agreements including grants or contracts from various agencies of the U.S. government to support the reporting entity's research and development activities.
Inventory
Schedule of Inventory, Current [Table Text Block]
Revenue, percentage
Revenue Percentage
Percentage of revenue represented from National Institutes of Health and BARDA.
Schedule of components of income tax expense (benefit)
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
Schedule of deferred tax assets and liabilities
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
Schedule of effective income tax rate reconciliation
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
Accrued Expenses
Accrued expenses and other current liabilities [Text Block]
The entire disclosure for accrued liabilities and other current liabilities at the end of the reporting period.
Loss Contingencies [Table]
Loss Contingencies [Table]
Litigation Case [Axis]
Litigation Case [Axis]
Litigation Case Type [Domain]
Litigation Case [Domain]
License Agreement litigation
License Agreement Litigation [Member]
License Agreement Litigation [Member]
Litigation Status [Axis]
Litigation Status [Axis]
Litigation Status [Domain]
Litigation Status [Domain]
Settled Litigation
Settled Litigation [Member]
Loss Contingencies [Line Items]
Loss Contingencies [Line Items]
Rent reduction
Rent Reduction
The amount of reduced monthly rent for the research and development facility due to the addendum to the Commercial Lease.
Rent expense
Rent expense Facilities Lease
Rental expense incurred for facilities leased.
Number of courses to be delivered
Number of Courses To Be Delivered 1
Number of tecovirimat, also known as ST-246, courses to be delivered to the U.S. Strategic National Stockpile
Final order and judgment
Final Order And Judgment
Final order and judgment entered by the Court awarding damages to the Plaintiff.
Final order and judgment post-judgment interest
Final Order And Judgment Post-Judgment Interest
Final order and judgment post-judgment interest entered by the Court awarding damages to the Plaintiff.
Final order and judgment including interest
Final order and judgment plus interest
Final Order and Judgment entered by the Court awarding expectation damages, plus pre-judgment interest, and certain permitted legal fees, costs, and expenses to Plaintiff.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Statement of Cash Flows [Abstract]
Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]
Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]
Cash flows from operating activities:
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net loss
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Stock-based compensation
Share-based Compensation
Gain on sale of assets
Gain (Loss) on Disposition of Assets
Non-cash backstop fee
Stock Issuance Fees Expense
Stock Issuance Fees Expense
Loss on disposal of assets
Loss On Disposal Of Assets
Amount of loss on disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.
Non-cash interest expense
Other Noncash Expense
Interest expense on term loan - paid with restricted cash
Payment of Interest Expense
Payment of Interest Expense
Changes in assets and liabilities:
Increase (Decrease) in Operating Capital [Abstract]
Accounts receivable
Increase (Decrease) in Accounts Receivable
Inventory
Increase (Decrease) in Inventories
Deferred costs
Increase (Decrease) in Deferred Charges
Prepaid expenses and other current assets
Increase (Decrease) in Prepaid Expense
Other assets
Increase (Decrease) in Other Operating Assets
Deferred income taxes, net
Accounts payable, accrued expenses and other current liabilities
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Liabilities subject to compromise
Liabilities Subject to Compromise, Period Increase (Decrease)
Deferred revenue
Increase (Decrease) in Deferred Revenue
Other liabilities
Increase (Decrease) in Other Operating Liabilities
Net cash (used in) provided by operating activities
Net Cash Provided by (Used in) Operating Activities
Cash flows from investing activities:
Net Cash Provided by (Used in) Investing Activities [Abstract]
Capital expenditures
Payments to Acquire Property, Plant, and Equipment
Proceeds from sale of assets
Proceeds from Sale of Productive Assets
Return of collateral for surety bond
Collateral for Surety Bond
Collateral for Surety Bond
Restricted cash
Payments for (Proceeds from) Other Investing Activities
Net cash provided by (used in) investing activities
Net Cash Provided by (Used in) Investing Activities
Cash flows from financing activities:
Net Cash Provided by (Used in) Financing Activities [Abstract]
Net proceeds from exercise of warrants and options
Proceeds From Issuance Of Warrants and Options
The cash inflow associated with both the amount received from holders exercising their stock options and issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
Net proceeds from equity rights offering - net of offering costs
Proceeds from Equity Rights Offering, Net
Proceeds from Equity Rights Offering, Net
Payment of employee tax obligations for common stock tendered
Payments Related to Tax Withholding for Share-based Compensation
Debt issuance costs
Payments of Debt Issuance Costs
Repayment of long-term debt
Repayments of Long-term Debt
Excess tax benefit from stock-based compensation
Change In Excess Tax Benefit Stock-Based Compensation, Financing Activities
Amount of cash inflow/(outflow) from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.
Net cash provided by (used in) financing activities
Net Cash Provided by (Used in) Financing Activities
Net (decrease) increase in cash and cash equivalents
Cash and Cash Equivalents, Period Increase (Decrease)
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosures of cash flows information:
Supplemental Cash Flow Information [Abstract]
Portion of Term Loan paid directly to PharmAthene by the Lender in satisfaction of the PharmAthene claim; such liability is part of the Liabilities Subject to Compromise line item
Notes Reduction
Cash interest paid on PharmAthene liability
Interest Paid on PharmAthene Liability
Interest Paid on PharmAthene Liability
Cash interest paid on Term Loan from restricted cash
Interest Paid on Term Loan From Restricted Cash
Interest Paid on Term Loan From Restricted Cash
Cash income taxes paid (refund)
Income Taxes Paid (Refund)
Income Taxes Paid (Refund)
Reclass of common stock warrant liability to additional paid-in capital upon warrant exercise
Reclass of Common Stock Warrant Liability To Additional Paid In Capital Upon Exercise
Value of reclass of common stock warrant liability to additional paid-in capital upon exercise in noncash financing activities.
Fair value of warrant, at issuance date, in connection with loan agreement and recorded as warrant liability
Liabilities Assumed
Stock options activity
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]
Stock appreciation rights award activity
Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Table Text Block]
Restricted stock and restricted stock units activity
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]
Debt Disclosure [Abstract]
US Treasury Rate
US Treasury Rate [Member]
US Treasury Rate [Member]
Effective interest rate (as a percent)
Debt Instrument, Interest Rate During Period
Interest expense, debt
Interest Expense, Debt
Interest paid on term loan
Interest Paid
Minimum cash requirement
Line of Credit Facility, Minimum Cash Requirement
Line of Credit Facility, Minimum Cash Requirement
Potential increase in interest rate
Line of Credit Facility, Debt Default, Increase in Interest Rate
Line of Credit Facility, Debt Default, Increase in Interest Rate
Costs incurred
Debt Issuance Cost
Fees and expenses
Debt Instrument, Fee Amount
Liabilities subject to compromise
Reorganization under Chapter 11 of US Bankruptcy Code Disclosure [Text Block]
Accounts payable - pre-petition
Liabilities subject to compromise, accounts payable
The amount of pre-petition trade accounts payable included in liabilities subject to compromise.
Accrual- PharmAthene Litigation
Loss Contingency Accrual
Other accrued expenses - pre-petition
Liabilities subject to compromise, other accrued expense
The amount of pre-petition accrued expense included in liabilities subject to compromise.
Liabilities subject to compromise
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive employee share-based awards, excluded
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Stock Compensation Plans
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract]
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory federal income tax rate
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent
State tax benefit
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent
Gain (loss) from fair value of common warrants
Effective Income Tax Rate Reconciliation Loss From Fair Value of Common Warrants
The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to changes in the fair value of common warrants.
Reorganization costs
Effective Income Tax Rate Reconciliation Loss From Reorganization Costs
The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to changes in reorganization costs.
Other
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Valuation allowance on deferred tax assets
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
Effective tax rate
Effective Income Tax Rate Reconciliation, Percent
Value of contract
Government Contract, Value of Award 1
Value of base contract award.
Contract value of manufacturing and delivery activities
Contract Value of Manufacturing and Delivery Activities
Contract value of manufacturing and delivery activities.
Number of courses under modified contract
Government Contract, Number of Courses Purchased Under Modified Contract
Government contract, number of courses to be purchased under modified contract.
Contract value of development and support activities
Contract Value of Development and Support Activities
Contract value of development and support activities
Government contract, number of free courses
Government Contract, Number of Free Courses
Number of courses of tecovirimat to be contributed to the Strategic Stockpile at no cost to the government.
Increase in payments for delivery of courses of TPOXX
Increase in payments for delivery of courses of TPOXX
Increase in payments for delivery of courses of TPOXX
Holdback amount pending FDA approval
Holdback amount pending FDA approval
Holdback amount pending FDA approval
Milestone payment
Milestone payment
Proceeds from milestone payment, Government contracts
Proceeds from advance payments under the BARDA contract
Proceeds from Advance Payments, Government Contracts
Proceeds from advance payments, government contracts
Proceeds from physical delivery of courses, government contracts
Proceeds From Physical Delivery Of Courses, Government Contracts
Proceeds from physical delivery of courses, government contract.
Future proceeds to be received from BARDA
Future proceeds to be received from BARDA
Future proceeds to be received from BARDA
Future proceeds to be received from the future deliveries of courses to the government
Future proceeds to be received from the future deliveries of courses to the government
Future proceeds to be received from the future deliveries of courses to the government
Number of courses of TPOXX to be delivered to the government
Number of Courses to be Delivered by Company
Number of Courses to be Delivered by Company
Number of courses delivered and accepted at provisional dosage, once daily
Number Of Courses Delivered And Accepted At Provisional Dosage, Once Daily
Number of tecovirimat, also known as ST-246, courses delivered and accepted at the provisional dosage of 600 mg once daily to the U.S. Strategic National Stockpile.
Contract value of various options
Contract Value of Various Options
Contract value of various options exercisable at BARDA's discretion.
Amount of option to be received from BARDA for approval for extension of 84 moth expiry
Amount of option to be received from BARDA for approval for extension of 84 moth expiry
Amount of option to be received from BARDA for approval for extension of 84 moth expiry
Contract value, detail of option exercisable, development activities
Contract Value, Detail Of Option Exercisable, Development Activities
Contract value of option exercisable, amount represents exercisable option that would fund development and support activities, at BARDA's discretion.
Contract value, detail of option exercisable, production activities
Contract Value, Detail Of Option Exercisable, Production Activities
Contract value of option exercisable, amount represents exercisable option that would fund production activities, at BARDA's discretion.
Contract value, option, FDA approval
Contract Value, Option, FDA Approval
Contract value of option exercisable, FDA approval for extension to 84-month expiry for Tecovirimat, at BARDA's discretion.
Deferred revenue
Deferred Revenue
Research and development revenue long-term contract
Research and Development Revenue Long-term Contract
Revenue earned during the period arising from research and development services provided under the terms of a long-term contract. May include government contracts and any other contract related to a particular project or product.
Number of active contracts
Number of Active Contracts
Number of active contracts.
Number of active grants
Number of Active Grants
Number of active grants
Debt
Debt Disclosure [Text Block]
Schedule of Restricted Cash and Cash Equivalents [Table]
Schedule of Restricted Cash and Cash Equivalents [Table]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and cash equivalents
Restricted Cash and Cash Equivalents
Statement of Stockholders' Equity [Abstract]
Statement [Table]
Statement [Table]
Additional Paid-in Capital
Additional Paid-in Capital [Member]
Retained Earnings
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss)
AOCI Attributable to Parent [Member]
Statement [Line Items]
Statement [Line Items]
Increase (Decrease) in Stockholders' Equity
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Total stockholders' equity (in shares)
Total stockholders' equity
Issuance of common stock upon exercise of RSU's, shares
Stock Issued During Period, Shares, Conversion of Units
Issuance of common stock upon exercise of RSU's, value
Stock Issued During Period, Value, Conversion of Units
Issuance of common stock upon exercise of stock options and warrants (in shares)
Issuance of common stock upon exercise of stock options and warrants
Proceeds from Stock Options Exercised
Stock-based compensation
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition
Change in excess tax benefit stock-based compensation, value
Payment of common stock tendered for employee stock-based compensation tax obligations (in shares)
Shares Paid for Tax Withholding for Share Based Compensation
Payment of common stock tendered for employee stock-based compensation tax obligations
Issuance of common stock associated with rights offering, value
Stock Issued During Period, Value, Rights Offering
Stock Issued During Period, Value, Rights Offering
Issuance of common stock associated with backstop agreement, shares
Stock Issued During Period, Shares, Backstop Agreement
Stock Issued During Period, Shares, Backstop Agreement
Issuance of common stock associated with backstop agreement, value
Stock Issued During Period, Value, Backstop Agreement
Stock Issued During Period, Value, Backstop Agreement
Total stockholders' equity (in shares)
Total stockholders' equity
Legal and expert fees accrual - PharmAthene Litigation
Liabilities subject to compromise, loss contingency legal fees
The amount of pre-petition loss contingency liability representing legal and expert fees accrued and included in liabilities subject to compromise.
Surety bond
Surety bond
Amount of surety bond.
Payment to post collateral for surety bond
Payment to Post Collateral for Surety Bond
Payment to post collateral for surety bond.
Expense directly attributable to the implementation of the plan
Liabilities Subject to Compromise, Expense (Income) Items
Reorganization payments
Reorganization Payments
The amount the Company paid for reorganization items.